Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIOPEL 5 (HCC-1) trial on hepatocellular carcinoma family of tumours in young patients
2005-000427-42Phase 2Completed
- Sponsor
- UK Children's Cancer Study Group
- Start
- Mar 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide and cyclophosphamide in hepatocellular carcinoma (HCC), sponsored by UK Children's Cancer Study Group. Primary endpoint: Complete remission status. Started Mar 2005; status: completed.
02
Drugs
thalidomidecyclophosphamide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2005-000427-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000427-42.